GlaxoSmithKline: basic facts
April, 2003 Price Cut for AZT, 3TC and Combivir
Investor Campaign to Obtain Voluntary Licenses to GSK Drugs
Political Donations and Lobbying, USA
- SmithKline Beecham
Drugs Related to IPR Disputes
- GlaxoWellcome has moved to halt exportation of Duovir (generic combivir) by Cipla, a generic
pharmaceutical company in India, into Ghana. Combivir is a drug which is a combination of AZT and 3TC. GlaxoWellcome
claims it has exclusive rights to market these drugs in Ghana, citing four specific patents. According to
Ghana's patent office, however, three of these patents were issued before Ghana allowed patent protection
for pharmaceuticals, and therefore are invalid, and the fourth applies only to chrystalline 3TC, which is
not included in Duovir.
- February 19, 2001. Toby Kasper, posting to the Pharm-policy list.
Glaxo's claims of patent protection on antiretrovirals in Ghana.
- February 11, 2001. S. Whitaker.
Medicines in Ghana Editorial in the Parmaceutical Journal Vol 266 No 7134. Also includes
a response from GlaxoSmithKline.
- August 10, 2000. Letter from GlaxoWellcome to CIPLA: Importation of Duovir into Ghana.
Here is an
html verison. Here is a
- September 22, 2000.
Response to above letter from A. A. Thorton, attorney for Cipla.
- December 2, 2000,
Sarah Boseley, in the Guardian (UK),
Glaxo stops Africans buying cheap Aids drugs
- December 1, 2000,
Mark Schoofs, in The Wall Street Journal,
Glaxo Attempts to Block Access To Generic AIDS Drugs in Ghana
- December, 2000, Russell Mokhiber and Robert Weissman in the Multinational Monitor.
Enemies of the Future:
The 10 Worst Corporations of 2000.
- November 9, 2000, Accra Mail,
Glaxo Wellcome Stops AIDS Drug Import to Ghana
- November 3, 2000, Gauri Kamath, in Economic Times,
Cipla stops export to Ghana on Glaxo allegations
In a dispute similar to that involving Ghana, GlaxoWellcome has moved to prevent Ciphla from exporting Duovir
Oxfam's Cut the Cost Campaign|
The British non-proft organization Oxfam has targetted GlaxoSmithKline in their new campaign to
lower medicine prices around the world.
- Accelerating Access Initiative
On May 11, 2000, GlaxoWellcome, Bristol Myers Squibb, Merck, Boehringer-Ingelheim,
and Roche entered into this initiative along with UNAIDS, the World Health Organization,
UNICEF, the World Bank, and the UN Development Program. The goal is to improve access
to HIV/AIDS drugs in developing countries. Drug donations are negotiated on a
country-by-country basis. To date, the program has succeeded in getting
drugs donated for relatively small programs in a few countries.
PUBLIC RELATIONS OFFICERS
WASHINGTON, DC OFFICE
- United Kingdom
- Martin Sutton 44 (020) 8966-8000
- Alan Chandler 44 (020) 8975-2290
- Philip Thomson 44 (020) 8966-8000
- United States
- Julie Dean (919) 483-2839
- Jeremy Heymsfeld (215) 751-5166
- Rick Sluder (919) 483-2839
1500 K St., NW #605
Washington, DC 20005
Janie Kinney, V.P. for
Federal Government Relations
and Public Policy
CPT Intellectual Property and Healthcare page
CPT Companies page